Müller-Tidow C - Search Results

1

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.

Récher C, Röllig C, Bérard E, Bertoli S, Dumas PY, Tavitian S, Kramer M, Serve H, Bornhäuser M, Platzbecker U, Müller-Tidow C, Baldus CD, Martínez-Cuadrón D, Serrano J, Martínez-Sánchez P, Arbolí ER, Gil C, Bergua J, Bernal T, de la Fuente Burguera A, Delabesse E, Bidet A, Pigneux A, Montesinos P. Récher C, et al. Leukemia. 2022 Apr;36(4):913-922. doi: 10.1038/s41375-021-01425-9. Epub 2021 Nov 13. Leukemia. 2022. PMID: 34775483 Free PMC article.

2

Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.

Padró T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H, Büchner T, Kessler T, Herrera F, Kienast J, Müller-Tidow C, Serve H, Berdel WE, Mesters RM. Padró T, et al. Leukemia. 2002 Jul;16(7):1302-10. doi: 10.1038/sj.leu.2402534. Leukemia. 2002. PMID: 12094254 Clinical Trial.

3

[Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].

Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H. Müller-Tidow C, et al. Dtsch Med Wochenschr. 2002 Oct 18;127(42):2195-200. doi: 10.1055/s-2002-34942. Dtsch Med Wochenschr. 2002. PMID: 12397548 German.

4

Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.

Steffen B, Serve H, Berdel WE, Agrawal S, Linggi B, Büchner T, Hiebert SW, Müller-Tidow C. Steffen B, et al. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8448-53. doi: 10.1073/pnas.1330293100. Epub 2003 Jun 20. Proc Natl Acad Sci U S A. 2003. PMID: 12819347 Free PMC article.

5

E- and A-type cyclins as markers for cancer diagnosis and prognosis.

Yasmeen A, Berdel WE, Serve H, Müller-Tidow C. Yasmeen A, et al. Expert Rev Mol Diagn. 2003 Sep;3(5):617-33. doi: 10.1586/14737159.3.5.617. Expert Rev Mol Diagn. 2003. PMID: 14510182 Review.

6

Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia.

Tiesmeier J, Czwalinna A, Müller-Tidow C, Krauter J, Serve H, Heil G, Ganser A, Verbeek W. Tiesmeier J, et al. Br J Haematol. 2003 Nov;123(3):413-9. doi: 10.1046/j.1365-2141.2003.04618.x. Br J Haematol. 2003. PMID: 14616999 Free article.

7

Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia.

Müller-Tidow C, Metzelder SK, Buerger H, Packeisen J, Ganser A, Heil G, Kügler K, Adigüzel G, Schwäble J, Steffen B, Ludwig WD, Heinecke A, Büchner T, Berdel WE, Serve H. Müller-Tidow C, et al. Leukemia. 2004 Apr;18(4):720-6. doi: 10.1038/sj.leu.2403296. Leukemia. 2004. PMID: 14973498

8

Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.

Tiesmeier J, Müller-Tidow C, Westermann A, Czwalinna A, Hoffmann M, Krauter J, Heil G, Ganser A, Serve H, Verbeek W. Tiesmeier J, et al. Leuk Res. 2004 Oct;28(10):1069-74. doi: 10.1016/j.leukres.2004.02.009. Leuk Res. 2004. PMID: 15289019

9

Signal transduction of oncogenic Flt3.

Choudhary C, Müller-Tidow C, Berdel WE, Serve H. Choudhary C, et al. Int J Hematol. 2005 Aug;82(2):93-9. doi: 10.1532/IJH97.05090. Int J Hematol. 2005. PMID: 16146838 Review.

10

The molecular pathogenesis of acute myeloid leukemia.

Steffen B, Müller-Tidow C, Schwäble J, Berdel WE, Serve H. Steffen B, et al. Crit Rev Oncol Hematol. 2005 Nov;56(2):195-221. doi: 10.1016/j.critrevonc.2004.10.012. Epub 2005 Oct 19. Crit Rev Oncol Hematol. 2005. PMID: 16236521 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

506 results

Search Page